Stockscreener 앱 받기
86.80
1.80%
-1.59
시장 영업 전:
88.01
1.21
+1.39%
Arcellx Inc 주식(ACLX)의 최신 뉴스
FY2025 EPS Estimates for Arcellx Cut by Cantor Fitzgerald - MarketBeat
Analyzing recovery setups for Arcellx Inc. investors2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Arcellx (NASDAQ:ACLX) Rating Lowered to Hold at Cantor Fitzgerald - MarketBeat
Automated trading signals detected on Arcellx Inc.July 2025 Update & Verified Momentum Watchlists - newser.com
Using data filters to optimize entry into Arcellx Inc.Market Weekly Review & Expert Curated Trade Ideas - newser.com
Is Arcellx Inc. showing signs of accumulationWeekly Market Summary & Fast Entry High Yield Tips - newser.com
Arcellx assumed with a Neutral at Cantor Fitzgerald - TipRanks
Why Arcellx (ACLX) Is Up 7.5% After Insider Sales and Optimism on CAR-T Regulatory Outlook - Yahoo Finance
Arcellx's (ACLX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
ACLX: Cantor Fitzgerald Assumes Coverage with Neutral Rating | A - GuruFocus
What analyst consensus says on Arcellx Inc. stockWeekly Gains Report & Reliable Intraday Trade Plans - newser.com
Arcellx Inc Stock Analysis and ForecastIndustrial Stocks Review & Free Exceptional Market Positioning - earlytimes.in
CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Insider Selling: Michelle Gilson Sells 5,946 Shares of Arcellx Inc (ACLX) - GuruFocus
Arcellx CFO Gilson sells $511k in ACLX stock - Investing.com
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Efficacy, Safety, and Financial Position - TipRanks
Arcellx (NASDAQ:ACLX) Biggest Nasdaq Stocks Mirror Biotech Progress - Kalkine Media
Could Analyst Optimism on Neurotoxicity Give Arcellx (ACLX) an Edge in CAR-T Competition? - Sahm
Will Arcellx Inc. see short term momentumEarnings Recap Summary & Growth Focused Stock Reports - newser.com
Published on: 2025-10-05 04:40:22 - newser.com
A Fresh Look at Arcellx (ACLX) Valuation Following Scotiabank’s Regulatory Optimism and CAR-T Therapy Developments - Sahm
Will Arcellx Inc. bounce back from current supportMarket Movers & Fast Entry High Yield Tips - newser.com
What moving averages say about Arcellx Inc.July 2025 Sentiment & Expert Verified Movement Alerts - newser.com
BofA Securities Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $112 - 富途牛牛
Christopher Heery Sells 21,034 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
Arcellx CMO Heery sells $5851 in ACLX stock By Investing.com - Investing.com Nigeria
Arcellx CMO Heery sells $5851 in ACLX stock - Investing.com India
What drives Arcellx Inc stock priceEx-Dividend Date Alerts & Budget Friendly Growth - earlytimes.in
Using portfolio simulators with Arcellx Inc. includedPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com
Arcellx CMO Heery sells $993k in ACLX stock - Investing.com India
Arcellx CMO Heery sells $993k in ACLX stock By Investing.com - Investing.com Nigeria
Arcellx (NASDAQ:ACLX) Insider Sells $993,167.52 in Stock - MarketBeat
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $121 - 富途牛牛
Atle Fund Management AB Sells 18,439 Shares of Arcellx, Inc. $ACLX - MarketBeat
Arcellx Inc’s Strong Positioning and Financial Stability Support Buy Rating Amid Anticipated FDA Approval - TipRanks
Strs Ohio Acquires New Stake in Arcellx, Inc. $ACLX - MarketBeat
Christopher Heery Sells 300 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
Arcellx (NASDAQ:ACLX) Insider Christopher Heery Sells 3,343 Shares - MarketBeat
5.74%
자본화:
|
볼륨(24시간):